Ensem Therapeutics Secures $67 Million Series A Financing to Advance AI-Driven Drug Discovery Platform Targeting 'Undruggable' Oncology Targets

April 7: Tech & AI pharmaceutical company Ensem Therapeutics (hereinafter referred to as "Ensem") announced the completion of a $67 million Series A financing round and officially came out of stealth mode. This round of financing was led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, Inc., and CBC Group. The funds raised in this round will be used for pipeline advancement and platform development.

Ensem Therapeutics, Inc. has gathered numerous pioneering scientists in the field and officially commenced operations in Boston in mid-2021. According to the company’s official website, Ensem is a Tech & AI-driven pharmaceutical company primarily focused on pipeline development. It targets high-value and “difficult-to-drug” targets by developing innovative small-molecule drugs based on protein/RNA dynamic conformational changes (Kinetic Ensemble-based Drug Discovery). The company is currently concentrating on the field of oncology treatment, with plans to expand into genetic disorders and other disease areas in the future.